Flash Finance

Zydus Lifesciences LimitedZYDUSLIFECorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Mar 2026 14 quarters of data
Consolidated Standalone
₹1,123.00
MCap ₹112,020 Cr · P/E 22.1
Zydus Lifesciences Limited — Stock analysis & AI research Zydus Lifesciences Limited — Multibagger AI analysis Zydus Lifesciences Limited — Seasonality — best & worst months Zydus Lifesciences Limited — Technical indicators & charts Zydus Lifesciences Limited — Technical setup — score, trend, support & resistance Zydus Lifesciences Limited — Ascending Triangle pattern forming Zydus Lifesciences Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 Stocks Cheaper Than Their Industry📋 High Profit Growth Stocks📋 GARP Stocks (PEG Below 1) ⚖️ vs Sun Pharmaceutical⚖️ vs Laurus Labs 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹7,587 Cr
Sales · Mar 2026
+16.2% YoY
₹2,554 Cr
Operating Profit · Mar 2026
+20.2% YoY
33.7%
OPM % · Mar 2026
+3.4% YoY
₹1,341 Cr
Net Profit · Mar 2026
+14.5% YoY
₹12.65
EPS · Mar 2026
+8.7% YoY

📝 Zydus Lifesciences Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Zydus Lifesciences Limited reported revenue of ₹7,587 crore for the quarter ended March 2026 (Q4 FY26), up 16.2% from ₹6,528 crore in the same quarter last year, and up 10.5% sequentially over the December 2025 quarter.

Net profit rose 14.5% year-on-year to ₹1,341 crore, from ₹1,171 crore. Earnings per share (EPS) came in at ₹12.65.

Operating profit stood at ₹2,554 crore — an operating margin (OPM) of 33.7%, compared with 32.6% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Zydus Lifesciences Limited posted revenue of ₹27,148 crore, a growth of 16.8% over FY25, with a net profit of ₹5,070 crore (up 12.0% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹27,148 crore with a net profit of ₹5,070 crore.

Valuation snapshot

At the current price of ₹1,123.00, ZYDUSLIFE has a market capitalisation of ₹112,020 crore and a trailing P/E of about 22.1.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 4th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 75.01%, foreign institutional investors (FIIs) 7.05%, domestic institutional investors (DIIs) 11.28%, public shareholders 6.66% of Zydus Lifesciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹112,020 Cr
Current Price ?
₹1,123.0
P/E ?
22.10below ind
Industry P/E ?
35.00
P/B ?
4.13
P/S ?
4.13
P/FCF ?
-211.36
Enterprise Value ?
₹124,516 Cr
EV/EBITDA ?
14.69
PEG ?
0.69
Earnings Yield ?
5.7%
Dividend Yield ?
0.09%
Profitability & Returns
Sales (TTM) ?
₹27,148 Cr
OPM ?
31.2%
Profit after tax (TTM) ?
₹5,070 Cr
EPS (TTM) ?
₹50.82
ROCE ?
21.0%
ROE ?
18.7%
ROA ?
9.7%
Growth
Sales — latest qtr ?
₹7,587 Cr
PAT — latest qtr ?
₹1,341 Cr
YoY qtr sales growth ?
16.2%
YoY qtr profit growth ?
14.5%
Sales growth (3y) ?
16%
Sales growth (5y) ?
12%
Profit growth (3y) ?
32%
Profit growth (5y) ?
19%
Financial Health
Debt ?
₹12,496 Cr
Debt to Equity ?
0.46
Interest Coverage ?
16.1
Current Ratio ?
N/A
Ownership
Promoter holding ?
75.01%
Change in promoter holding ?
0.01%
Pledged percentage ?
N/A
Market
Return 3 months ?
-1.8%
Return 6 months ?
19.0%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 4,3625,0115,1404,3694,5055,5346,2085,2375,2696,5286,5746,1236,8647,587 +16.2% +10.5%
Operating Profit 9561,1931,5051,1461,1021,6302,0841,4611,3882,1262,0882,0161,8162,554 +20.2% +40.6%
Other Income 3883365438156636857811557526-263 -426.3% -1111.5%
Interest 335118920353225327785101130123 +60.6% -5.4%
Depreciation 182182180184195205215234229238238302360508 +113.5% +41.1%
Profit Before Tax 7804431,3291,0079261,5471,9001,2711,1841,6721,9211,6871,3531,660 -0.7% +22.7%
Net Profit 6232971,0878017901,1821,4209111,0261,1711,4671,2391,0231,341 +14.5% +31.1%
EPS 6.152.9410.747.917.8011.6914.119.0610.1711.6414.5812.5110.3612.65 +8.7% +22.1%
OPM % 21.9% 23.8% 29.3% 26.2% 24.5% 29.5% 33.6% 27.9% 26.3% 32.6% 31.8% 32.9% 26.5% 33.7% +3.4% +27.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹23,242 Cr ₹27,148 Cr ₹27,148 Cr +16.8%
Operating Profit ₹7,059 Cr ₹8,474 Cr ₹8,474 Cr +20.1%
OPM % 30.37% 31.22% 31.22% +2.8%
NPM % 19.48% 18.67% 18.67% -4.2%
Other Income ₹269 Cr ₹-7 Cr ₹-7 Cr -102.6%
Depreciation ₹916 Cr ₹1,408 Cr ₹1,408 Cr +53.8%
Interest ₹166 Cr ₹439 Cr ₹439 Cr +164.4%
EBIT ₹6,143 Cr ₹7,066 Cr ₹7,066 Cr +15.0%
PBT ₹6,027 Cr ₹6,621 Cr ₹6,621 Cr +9.9%
Tax ₹1,232 Cr ₹434 Cr ₹434 Cr -64.8%
Net Profit ₹4,528 Cr ₹5,070 Cr ₹5,070 Cr +12.0%
EPS ₹44.98 ₹50.10 ₹50.10 +11.4%
Material Cost ₹4,925 Cr ₹1,877 Cr ₹1,877 Cr -61.9%
Employee Cost ₹2,734 Cr ₹1,005 Cr ₹1,005 Cr -63.2%
Extraordinary Items ₹-220 Cr — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 101101101101 +0.0%
Reserves 17,41519,72923,85227,011 +13.2%
Borrowings 1,1958043,21312,496 +288.9%
Other Liabilities 6,8518,2019,52312,799 +34.4%
Total Liabilities 25,56228,83436,68952,407 +42.8%
Fixed Assets 11,52112,36813,13426,639 +102.8%
CWIP 1,2012,4232,6921,166 -56.7%
Investments 1,5471,2206,4087,540 +17.7%
Other Assets 11,29412,82214,45617,062 +18.0%
Total Assets 25,56228,83436,68952,407 +42.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 2,6893,2286,7772,117 -68.8%
Cash from Investing Activity 1,178-1,492-8,377-8,296 +1.0%
Cash from Financing Activity -4,400-1,8102,0145,807 +188.3%
Net Cash Flow -534-75414-373 -190.1%
Free Cash Flow 1,6972,3455,116-530 -110.4%
CFO/OP 85%84%122%44% -63.9%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 94976373 +15.9%
Inventory Days 197202227282 +24.2%
Days Payable 123125133142 +6.8%
Cash Conversion Cycle 168175158212 +34.2%
Working Capital Days 7088337 +1133.3%
ROCE % 15%22%24%21% -12.5%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 75.00%75.00%75.00%75.00%75.01% +0.0%
FIIs 7.13%7.34%7.06%6.95%7.05% +1.4%
DIIs 11.09%10.86%11.08%11.20%11.28% +0.7%
Government 0.04%0.00%0.00%0.00%— —
Public 6.74%6.81%6.86%6.86%6.66% -2.9%
No. of Shareholders 3,86,1273,96,1054,03,2664,18,3143,82,067 -8.7%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Zydus Lifesciences Limited's revenue in Q4 FY26?
Zydus Lifesciences Limited reported revenue of ₹7,587 crore for the quarter ended March 2026 (Q4 FY26), up 16.2% from ₹6,528 crore in the same quarter last year, and up 10.5% sequentially over the December 2025 quarter.
What was Zydus Lifesciences Limited's net profit in Q4 FY26?
Net profit rose 14.5% year-on-year to ₹1,341 crore, from ₹1,171 crore. Earnings per share (EPS) came in at ₹12.65.
What is ZYDUSLIFE's market capitalisation and P/E ratio?
At the current price of ₹1,123.00, ZYDUSLIFE has a market capitalisation of ₹112,020 crore and a trailing P/E of about 22.1.
Who owns Zydus Lifesciences Limited? (shareholding pattern)
As of Sep 2026, promoters held 75.01%, foreign institutional investors (FIIs) 7.05%, domestic institutional investors (DIIs) 11.28%, public shareholders 6.66% of Zydus Lifesciences Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI